LC-MS/MS quantitation of ribavirin in serum and identification of endogenous isobaric interferences

被引:18
作者
Danso, Darlington [1 ]
Langman, Loralie J. [1 ]
Snozek, Christine L. H. [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
Ribavirin; Therapeutic drug monitoring; Hepatitis C; Mass spectrometry; Interference; SUSTAINED VIROLOGICAL RESPONSE; CHRONIC HEPATITIS-C; PLASMA-CONCENTRATION; THERAPY;
D O I
10.1016/j.cca.2011.07.016
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Ribavirin is a nucleoside analog used in treatment of chronic hepatitis C. It is associated with severe, dose-dependent toxicities, including hemolytic anemia. To facilitate therapeutic drug monitoring, a liquid chromatography-tandem mass spectrometry method was validated for quantitation of ribavirin in serum. Methods: After protein precipitation, ribavirin is quantitated using a (13)C(5)-ribavirin internal standard, on a Hypercarb analytical column designed for retention of polar analytes. Results: The analytical method shows excellent precision, sensitivity, and specificity. In vitro drug stability was also assessed. Interestingly, endogenous isobaric compounds were noted in both human and bovine serum; these could be chromatographically separated from the ribavirin peak. Addition of exogenous uridine and cytosine increases the size of the isobaric peaks, suggesting that these compounds are the source of the endogenous interference. Conclusions: This method uses mass spectrometric transitions that have been used in other published methods, but also separates ribavirin from isobaric peaks that were not described. These peaks were determined to be endogenous nucleosides. Laboratories quantitating ribavirin in biological matrices should be aware of the potential for isobaric interferences, and take steps to chromatographically separate them from the ribavirin peak for accurate quantitation. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:2332 / 2335
页数:4
相关论文
共 12 条
[1]   Ion suppression in mass spectrometry [J].
Annesley, TM .
CLINICAL CHEMISTRY, 2003, 49 (07) :1041-1044
[2]   Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy [J].
Brochot, Etienne ;
Castelain, Sandrine ;
Duverlie, Gilles ;
Capron, Dominique ;
Nguyen-Khac, Eric ;
Francois, Catherine .
ANTIVIRAL THERAPY, 2010, 15 (05) :687-695
[3]   Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon α-2b and ribavirin combination after liver transplantation [J].
Dumortier, J. ;
Ducos, E. ;
Scoazec, J. -Y. ;
Chevallier, P. ;
Boillot, O. ;
Gagnieu, M. -C. .
JOURNAL OF VIRAL HEPATITIS, 2006, 13 (08) :538-543
[4]   Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response [J].
Furusyo, Norihiro ;
Murata, Masayuki ;
Ogawa, Eiichi ;
Toyoda, Kazuhiro ;
Ihara, Takeshi ;
Ikezaki, Hiroaki ;
Hayashi, Takeo ;
Koga, Tsunehisa ;
Kainuma, Mosaburo ;
Hayashi, Jun .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) :1127-1139
[5]   The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon [J].
Marucco, D. Aguilar ;
de Requena, D. Gonzalez ;
Bonora, S. ;
Tettoni, C. ;
Bonasso, M. ;
De Blasi, T. ;
D'Avolio, A. ;
Sciandra, M. ;
Siccardi, M. ;
Baietto, L. ;
Trentini, L. ;
Sinicco, A. ;
Cariti, G. ;
Di Perri, G. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (04) :919-924
[6]  
Maynard M, 2008, ANTIVIR THER, V13, P607
[7]   Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C [J].
Morello, Judit ;
Rodriguez-Novoa, Sonia ;
Jimenez-Nacher, Inmaculada ;
Soriano, Vincent .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (06) :1174-1180
[8]   Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection [J].
Pedersen, C. ;
Alsio, A. ;
Lagging, M. ;
Langeland, N. ;
Farkkila, M. ;
Buhl, M. Rauning ;
Morch, K. ;
Westin, J. ;
Sangfelt, P. ;
Norkrans, G. ;
Christensen, P. Brehm .
JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) :245-251
[9]   Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C [J].
Sauvage, Francois-Ludovic ;
Stanke-Labesque, Francoise ;
Gagnieu, Marie-Claude ;
Jourdil, Jean-Francois ;
Babany, Gerard ;
Marquet, Pierre .
THERAPEUTIC DRUG MONITORING, 2009, 31 (03) :374-381
[10]   Ribavirin Plasma Concentration Measurements in Patients With Hepatitis C: Early Ribavirin Concentrations Predict Steady-State Concentrations [J].
Slavenburg, Serena ;
Huntjens-Fleuren, Hanneke W. H. A. ;
Dofferhoff, Ton S. M. ;
Richter, Clemens ;
Koopmans, Peter P. ;
Verwey-Van Wissen, Corrien P. W. G. M. ;
Drenth, Joost P. H. ;
Burger, David M. .
THERAPEUTIC DRUG MONITORING, 2011, 33 (01) :40-44